RAVN Årsrapport 2015 141016 trykk pk - Folkehelseinstituttet · RAVN 2015 • Norwegian Institute of Public Health 2 Published by Norwegian Institute of Public Health September 2016

www.fhi.no

Published by Norwegian Institute of Public HealthSeptember 2016P. O. Box 4404 NydalenNO-0403 OsloTel: 21 07 70 00

Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2015

RAVNResistensovervåking av virus i Norge Resistance against Antivirals in Norway

2016

RAVN 2015 omslag.indd 1 14.10.2016 15.39

RAVN 2015 • Norwegian Institute of Public Health

2

PublishedbyNorwegianInstituteofPublicHealthSeptember2016

Title:UsageofAntiviralsandtheOccurrenceofAntiviralResistanceinNorway2015.RAVN

Ordering:Electroniccopy(PDF):www.fhi.no/en/publ/www.fhi.no/publPrintedcopycanbeorderedfrom:NorwegianInstituteofPublicHealthP.O.Box4404NydalenNO-0403Oslopublikasjon@fhi.noTel:+4721078200

Coverdesign:PerKristianSvendsen/GreteSøimer

Printedcopies:500

CoverPhoto:Colourbox.comISBN978-82-8082-769-2(printedcopy)ISBN978-82-8082-770-8(electroniccopy)


3


4

Anita Kanestrøm RAVN, Norwegian Institute of Public Health (NIPH)


5


6


7


8


9


10


11


12


13


14


15

www.norpd.no


16


17


18

http://ecdc.europa.eu/en/publications/Publications/neuraminidase-inhibitors-flu-consultation.pdf


19


20


21

http://www.unaids.org/en/resources/campaigns/HowAIDSchangedeverything/factsheet


22


23

https://www.kvalitetsregistre.no/registers/557/resultater/556


24


25


26


27


28


29


30


31


32


33


34


35


36


37


38


39


40

Johan Lennerstrand, Associate professor Clinical Microbiology, Department of Medical Sciences, Uppsala University Hospital [email protected], 18.08.2016


41


42

NDA No data available *Prevalence of 5 - 10% at baseline for DAA treatment naive patients when using Sanger sequencing method (20% cut-off). ** Natural NS3 polymorphism of 100% at baseline for genotype 3

NDA No data available *Prevalence of 5 - 10% at baseline for DAA treatment naive patients when using Sanger sequencing method (20% cut-off). Table 1 and 2 references: Lontok et al, Hepatology 2015 ; Sarrazin, J Hepatology 2016 ; Wyles D, AASLD presentation 2015 ; NG T et al, AASLD poster 2015 ; NG T et al, CROI poster 2014; Liu R et al, AAC 2015 ; Lahser FC et al, AAC 2016 ; Muir AJ EASL presentation 2016 ; Bergfors et al, AVR 2016.


43

Appendix A, HIV-1

Appendix A1. List of Surveillance Drug Resistance Mutations,SDRM, recommended by WHO.

HIV-1 RT and Protease Mutations For Drug Resistance Surveillance

NRTI Position M41 K65 D67 T69 K70 L74 V75 F77 Y115 F116 Q151 M184 L210 T215 K219

Mutation L R N, G, E D, Ins R, E V, I M, T, A, S L F Y M V, I W Y, F, I, S, C, D, V, E Q, E, N, R

NNRTI Position L100 K101 K103 V106 V179 Y181 Y188 G190 P225 M230

Mutation I E, P N,S M, A F C, I, V L, H, C A, S, E H L

PI Position L23 L24 D30 V32 M46 LI47 G48 I50 F53 I54 G73 L76 V82 N83 I84 I85 N88 L90

Mutation I I N I I V, A V, M V, L L, Y V, L, M, A, T, S S, T, C, A V A, T, F, S, C, M,L D V, A, C V D, S M

The following considerations were used to develop this list of drug resistance mutations* the mutations should cause or contribute to drug resistance, defined as being present on three or more of five expert lists of drug resistance mutations **. the mutations should not occur in untreated persons (i.e. they should be nonpolymorphic, and should not occur at highly polymorphic positions.), the mutation list should be applicable to all group M subtypes, and the mutation list should be simple, unambiguous, and parsimonious, excluding mutations resulting exceedingly rarely from drug pressure. * HIV-1 pretease and reverse transcriptase mutations for drug resistance surveillance, AIDS 2007, 21:215-223 Shafer R et al. Drug Resistance Mutations for Surveillance of Transmitted HIV-1 Drug-Resistance: 2009 Update, PLoS One 2009;4:e4724. Bennett DE et al. **ANRS drug resistance interpretation algorithm (2008.07),HIVdb drug resistance interpretation algorithm (4.3.7), IAS-USA Mutations Associated With Drug Resistance (March/April 2008), Los Alamos National Laboratories HIV Sequence database (2007), or Rega Institute Drug Resistance Interpretation Algorithm (7.1.1). The prevalence of all protease and RT mutations according to subtype and treatment can be found at http://hivdb.stanford.edu/cgi-bin/MutPrevBySubtypeRx.cgi.

www.fhi.no

Published by Norwegian Institute of Public HealthSeptember 2016P. O. Box 4404 NydalenNO-0403 OsloTel: 21 07 70 00

Usage of Antivirals and the Occurrence of Antiviral Resistance in Norway 2015

RAVNResistensovervåking av virus i Norge Resistance against Antivirals in Norway

2016

RAVN 2015 omslag.indd 1 14.10.2016 15.39

Documents

RAVN Årsrapport 2015 141016 trykk pk - Folkehelseinstituttet · RAVN 2015 • Norwegian Institute of Public Health 2 Published by Norwegian Institute of Public Health September 2016